Platelet-enhanced plasma: Characterization of a novel candidate resuscitation fluid's extracellular vesicle content, clotting parameters, and thrombin generation capacity

Transfusion. 2021 Jul;61(7):2179-2194. doi: 10.1111/trf.16423. Epub 2021 May 4.

Abstract

Background: Platelet transfusion is challenging in emergency medicine because of short platelet shelf life and stringent storage conditions. Platelet-derived extracellular vesicles (PEV) exhibit platelet-like properties. A plasma generated from expired platelet units rich in procoagulant PEV may be able to combine the benefits of plasma and platelets for resuscitation while increasing shelf life and utilizing an otherwise wasted resource.

Study design and methods: Freeze-thaw cycling of platelet-rich plasma (PRP) followed by centrifugation to remove platelet remnants was utilized to generate platelet-enhanced plasma (PEP). An in vitro model of dilutional coagulopathy was also designed and used to test PEP. Rotational thromboelastometry and calibrated automated thrombography were used to assess clotting and extracellular vesicles (EV) procoagulant activity. Capture arrays were used to specifically measure EV subpopulations of interest (ExoView™, NanoView Biosciences). Captured vesicles were quantified and labeled with Annexin-V-FITC, CD41-PE, and CD63-AF647. Platelet alpha granule content (platelet-derived growth factor AB, soluble P-selectin, vascular endothelial growth factor A, and neutrophil activating peptide 2-chemokine (C-X-C motif) ligand 7) was measured. Commercially available platelet lysates were also characterized.

Results: PEP is highly procoagulant, rich in growth factors, exhibits enhanced thrombin generation, and restores hemostasis within an in vitro model of dilutional coagulopathy. The predominant vesicle population were PEV with 7.0 × 109 CD41+PS+ EV/ml compared to 4.7 × 107 CD41+PS+ EV/ml in platelet-free plasma (p = .0079). Commercial lysates show impaired but rescuable clotting.

Discussion: PEP is a unique candidate resuscitation fluid containing high PEV concentration with preliminary evidence, indicating a potential for upscaling the approach using platelet concentrates. Commercial lysate manufacturer workflows may be suitable for this, but further optimization and characterization of PEP is required.

Keywords: ExoView; hemorrhage; hemostasis; platelet; platelet extracellular vesicle; procoagulant; resuscitation; trauma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Cell Count
  • Blood Coagulation*
  • Blood Platelets
  • Blood Preservation / methods
  • Extracellular Vesicles / transplantation*
  • Fibrinogen / analysis
  • Fibrinogen / pharmacology
  • Humans
  • Intercellular Signaling Peptides and Proteins / blood
  • P-Selectin / blood
  • Partial Thromboplastin Time
  • Plasma*
  • Platelet Membrane Glycoprotein IIb / blood
  • Platelet Transfusion*
  • Platelet-Rich Plasma
  • Prothrombin Time
  • Resuscitation*
  • Temperature
  • Thrombelastography
  • Thrombin / biosynthesis*
  • Time Factors

Substances

  • Intercellular Signaling Peptides and Proteins
  • P-Selectin
  • Platelet Membrane Glycoprotein IIb
  • Fibrinogen
  • Thrombin